A Phase 2 interventional study of TEZ and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 40 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-08-28.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 29th largest by enrollment, is one of 6 that started in 2016, is one of 8 in phase 2, and was the 12th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 6 started in 2016.
This study's enrollment of 74 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 58th largest by enrollment of the 116 interventional ones that give a count, is one of 15 that started in 2016, is one of 21 in phase 2, and was the 58th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, randomized, double-blind, placebo- and active-controlled, parallel group, multicenter study to evaluate the safety, tolerability, and efficacy of VX-440 in dual and triple combination with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F508del/F508del), or who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must have an eligible CFTR genotype:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo matched to VX-440/TEZ/IVA as triple combination for 4 weeks.
Drug: Matched Placebo
Participants received VX-440 200 milligram (mg) every 12 hours (q12h)/TEZ 100 mg once daily (qd)/IVA 150 mg q12h as triple combination for 4 weeks.
Drug: TEZ · Drug: IVA · Drug: VX-440
Participants received VX-440 200 mg q12h/TEZ 50 mg q12h/IVA 150 mg q12h as triple combination for 4 weeks.
Drug: TEZ · Drug: IVA · Drug: VX-440
Participants received VX-440 600 mg q12h/TEZ 50 mg q12h/IVA 300 mg q12h as triple combination for 4 weeks.
Drug: TEZ · Drug: IVA · Drug: VX-440
Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received placebo matched to VX-440 and TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
Drug: TEZ · Drug: IVA · Drug: Matched Placebo
Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received VX-440 600 mg q12h/ TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
Drug: TEZ · Drug: IVA · Drug: VX-440
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From first dose of Study Drug in the Treatment Period through Safety Follow-up Visit (Up to Day 57 for Part 1 and Day 85 for Part 2)
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline through Day 29
Absolute Change in Sweat Chloride Concentrations
Sweat samples were collected using an approved collection device.
Time frame: From Baseline through Day 29
Relative Change in ppFEV1
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline through Day 29
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From Baseline at Day 29
Pre-dose Plasma Concentration (Ctrough) of VX-440, TEZ, M1-TEZ, IVA and M1-IVA
Time frame: Predose at Day 8, Day 15 and Day 29
Of the 74 participants enrolled (47 participants in Part 1 and 27 participants in Part 2), 1 participant in Part 2 discontinued in the Run-in Period because continuation criteria were not met and was not randomized in the Treatment Period. Therefore, only 73 participants are included in the results below.
| Milestone | Part 1: Placebo - Cohort 1A and 1B Combined | Part 1 Cohort 1A: Triple Combination (TC) | Part 1 Cohort 1B: TC Low Dose | Part 1 Cohort 1B: TC High Dose | Part 2: TEZ/IVA | Part 2: TC-2 |
|---|---|---|---|---|---|---|
| Started | 11 | 9 | 9 | 18 | 6 | 20 |
| Completed | 11 | 9 | 9 | 18 | 6 | 20 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| participants | Part 1: Placebo - Cohort 1A and 1B Combined | Part 1 Cohort 1A: Triple Combination (TC) | Part 1 Cohort 1B: TC Low Dose | Part 1 Cohort 1B: TC High Dose | Part 2: TEZ/IVA | Part 2: TC-2 |
|---|---|---|---|---|---|---|
| Participants with AEs | 9 | 9 | 9 | 15 | 6 | 15 |
| Participants with SAEs | 0 | 0 | 0 | 2 | 2 | 1 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | Part 1: Placebo - Cohort 1A and 1B Combined | Part 1: TC-1A/ TC-1B-low Pooled | Part 1 Cohort 1B: TC High Dose | Part 2: TEZ/IVA | Part 2: TC-2 |
|---|---|---|---|---|---|
| Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | 1.4 (-2.7 to 5.5) | 10.0 (6.9 to 13.2) | 12.0 (8.8 to 15.2) | -2.5 (-7.2 to 2.2) | 9.5 (6.9 to 12.2) |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | Part 1: Placebo - Cohort 1A and 1B Combined | Part 1: TC-1A/ TC-1B-low Pooled | Part 1 Cohort 1B: TC High Dose | Part 2: TEZ/IVA | Part 2: TC-2 |
|---|---|---|---|---|---|
| Absolute Change in Sweat Chloride Concentrations | 1.6 (-6.2 to 9.4) | -20.7 (-26.6 to -14.7) | -33.1 (-39.1 to -27.1) | 2.1 (-10.9 to 15.1) | -31.3 (-38.6 to -24.1) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent change | Part 1: Placebo - Cohort 1A and 1B Combined | Part 1: TC-1A/ TC-1B-low Pooled | Part 1 Cohort 1B: TC High Dose | Part 2: TEZ/IVA | Part 2: TC-2 |
|---|---|---|---|---|---|
| Relative Change in ppFEV1 | 2.6 (-4.9 to 10.0) | 17.3 (11.5 to 23.2) | 21.7 (15.9 to 27.5) | -3.4 (-11.4 to 4.6) | 16.6 (12.1 to 21.1) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Part 1: Placebo - Cohort 1A and 1B Combined | Part 1: TC-1A/ TC-1B-low Pooled | Part 1 Cohort 1B: TC High Dose | Part 2: TEZ/IVA | Part 2: TC-2 |
|---|---|---|---|---|---|
| Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score | 2.2 (-6.2 to 10.6) | 18.3 (11.7 to 24.9) | 20.7 (14.2 to 27.1) | -7.8 (-14.8 to -0.8) | 12.3 (8.7 to 16.0) |
| nanogram per milliliter (ng/mL) | Part 1 Cohort 1A: Triple Combination (TC) | Part 1 Cohort 1B: TC Low Dose | Part 1 Cohort 1B: TC High Dose | Part 2: TEZ/IVA | Part 2: TC-2 |
|---|---|---|---|---|---|
| VX-440: Day 8 | 1670 ± 1910 | — | — | — | — |
| VX-440: Day 15 | 1840 ± 1460 | 1120 ± 707 | 8540 ± 6850 | — | 12900 ± 9940 |
| VX-440: Day 29 | 1090 ± 1010 | 1440 ± 1870 | 6650 ± 3500 | — | 10300 ± 7340 |
| TEZ: Day 8 | 810 ± 323 | — | — | — | — |
| TEZ: Day 15 | 749 ± 271 | 1070 ± 422 | 928 ± 558 | 2240 ± 1010 | 1250 ± 837 |
| TEZ: Day 29 | 761 ± 320 | 1040 ± 659 | 846 ± 514 | 1420 ± 565 | 893 ± 579 |
| M1-TEZ: Day 8 | 3160 ± 645 | — | — | — | — |
| M1-TEZ: Day 15 | 3490 ± 486 | 4610 ± 1170 | 3400 ± 1270 | 4640 ± 1730 | 3940 ± 1200 |
| M1-TEZ: Day 29 | 3560 ± 378 | 4180 ± 1950 | 3050 ± 1260 | 4060 ± 1560 | 3280 ± 1230 |
| IVA: Day 8 | 281 ± 167 | — | — | — | — |
| IVA: Day 15 | 245 ± 92.7 | 192 ± 97.0 | 233 ± 149 | 1040 ± 352 | 380 ± 312 |
| IVA: Day 29 | 209 ± 112 | 164 ± 108 | 219 ± 139 | 902 ± 344 | 290 ± 263 |
| M1-IVA: Day 8 | 795 ± 327 | — | — | — | — |
| M1-IVA: Day 15 | 854 ± 427 | 566 ± 245 | 850 ± 546 | 1640 ± 218 | 1220 ± 796 |
| M1-IVA: Day 29 | 702 ± 372 | 520 ± 338 | 792 ± 466 | 1580 ± 764 | 1080 ± 732 |
Collected over From first dose of Study Drug in the Treatment Period through Safety Follow-up Visit (Up to Day 57 for Part 1 and Day 85 for Part 2). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Placebo - Cohort 1A and 1B Combined | 0/11 (0%) | 0/11 (0%) | 9/11 (81.8%) |
| Part 1 Cohort 1A: Triple Combination (TC) | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Part 1 Cohort 1B: TC Low Dose | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Part 1 Cohort 1B: TC High Dose | 0/18 (0%) | 2/18 (11.1%) | 15/18 (83.3%) |
| Part 2: TEZ/IVA | 0/6 (0%) | 2/6 (33.3%) | 5/6 (83.3%) |
| Part 2: TC-2 | 0/20 (0%) | 1/20 (5%) | 15/20 (75%) |
| Event | Part 1: Placebo - Cohort 1A and 1B Combined | Part 1 Cohort 1A: Triple Combination (TC) | Part 1 Cohort 1B: TC Low Dose | Part 1 Cohort 1B: TC High Dose | Part 2: TEZ/IVA | Part 2: TC-2 |
|---|---|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/11 | 0/9 | 0/9 | 1/18 | 1/6 | 1/20 |
| Adjustment disorderPsychiatric disorders | 0/11 | 0/9 | 0/9 | 0/18 | 1/6 | 0/20 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 0/11 | 0/9 | 0/9 | 1/18 | 0/6 | 0/20 |
| Event | Part 1: Placebo - Cohort 1A and 1B Combined | Part 1 Cohort 1A: Triple Combination (TC) | Part 1 Cohort 1B: TC Low Dose | Part 1 Cohort 1B: TC High Dose | Part 2: TEZ/IVA | Part 2: TC-2 |
|---|---|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 2/11 | 6/9 | 0/9 | 2/18 | 0/6 | 2/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/11 | 3/9 | 1/9 | 1/18 | 0/6 | 5/20 |
| Viral upper respiratory tract infectionInfections and infestations | 1/11 | 0/9 | 2/9 | 2/18 | 2/6 | 1/20 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 3/11 | 1/9 | 1/9 | 1/18 | 1/6 | 3/20 |
| Upper respiratory tract infectionInfections and infestations | 0/11 | 2/9 | 0/9 | 2/18 | 0/6 | 2/20 |
| FatigueGeneral disorders | 0/11 | 0/9 | 2/9 | 0/18 | 0/6 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 1/11 | 1/9 | 1/9 | 2/18 | 0/6 | 4/20 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/11 | 0/9 | 0/9 | 0/18 | 0/6 | 1/20 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/11 | 0/9 | 0/9 | 0/18 | 0/6 | 1/20 |
| Respiration abnormalRespiratory, thoracic and mediastinal disorders | 2/11 | 0/9 | 0/9 | 0/18 | 0/6 | 1/20 |
| Age, Categorical(Participants) | Part 1: Placebo - Cohort 1A and 1B Combined | Part 1 Cohort 1A: Triple Combination (TC) | Part 1 Cohort 1B: TC Low Dose | Part 1 Cohort 1B: TC High Dose | Part 2: TEZ/IVA | Part 2: TC-2 | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 9 | 9 | 18 | 6 | 20 | 73 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part 1: Placebo - Cohort 1A and 1B Combined | Part 1 Cohort 1A: Triple Combination (TC) | Part 1 Cohort 1B: TC Low Dose | Part 1 Cohort 1B: TC High Dose | Part 2: TEZ/IVA | Part 2: TC-2 | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 3 | 1 | 0 | 4 | 11 |
| Male | 9 | 8 | 6 | 17 | 6 | 16 | 62 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Placebo - Cohort 1A and 1B Combined | Part 1 Cohort 1A: Triple Combination (TC) | Part 1 Cohort 1B: TC Low Dose | Part 1 Cohort 1B: TC High Dose | Part 2: TEZ/IVA | Part 2: TC-2 | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 0 | 0 | 1 | 3 |
| Not Hispanic or Latino | 10 | 9 | 8 | 17 | 6 | 18 | 68 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Part 1: Placebo - Cohort 1A and 1B Combined | Part 1 Cohort 1A: Triple Combination (TC) | Part 1 Cohort 1B: TC Low Dose | Part 1 Cohort 1B: TC High Dose | Part 2: TEZ/IVA | Part 2: TC-2 | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 10 | 9 | 9 | 18 | 6 | 20 | 72 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2016 to primary completion in Aug 2017, 10 months.
Results were first posted in Aug 2020, 3 years after primary completion. A results delay was requested in Aug 2018.
Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 10 months is below that.
Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →